Antioxidants and metallothionein levels in mercury-treated mice.
Acute effects of mercury on mouse blood, kidneys, and liver were evaluated. Mice received a single dose of mercuric chloride (HgCl2, 4.6 mg/kg, subcutaneously) for three consecutive days. We investigated the possible beneficial effects of antioxidant therapy (N-acetylcysteine (NAC) and diphenyl diselenide (PhSe)2) compared with the sodium salt of 2,3-dimercapto-1-propanesulfonic acid (DMPS), an effective chelating agent in HgCl2 exposure in mice. We also verified whether metallothionein (MT) induction might be involved in a possible mechanism of protection against HgCl2 poisoning and whether different treatments would modify MT levels and other toxicological parameters. The results demonstrated that HgCl2 exposure significantly inhibited delta-aminolevulinate dehydratase (delta-ALA-D) activity in liver and only DMPS treatment prevented the inhibitory effect. Mercuric chloride caused an increase in renal non-protein thiol groups (NPSH) and none of the treatments modified renal NPSH levels. Urea concentration was increased after HgCl2 exposure. NAC plus (PhSe)2 was partially effective in protecting against the effects of mercury. DMPS and (PhSe)2 were effective in restoring the increment in urea concentration caused by mercury. Thiobarbituric acid-reactive substances (TBARS), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) activities and ascorbic acid levels were not modified after mercury exposure. Mercuric chloride poisoning caused an increase in hepatic and renal MT levels and antioxidant treatments did not modify this parameter. Our data indicated a lack of therapeutic effect of the antioxidants tested.
Brandão
R
R
Departamento de Quimica, Centro de Ciencias Naturais e Exatas, Universidade Federal de Santa Maria, 97105-900, Santa Maria, RS, Brazil.
Santos
F W
FW
Farina
M
M
Zeni
G
G
Bohrer
D
D
Rocha
J B T
JB
Nogueira
C W
CW
D000111:Acetylcysteine / Q000627:therapeutic use*; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001555:Benzene Derivatives / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D002614:Chelating Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D008627:Mercuric Chloride / Q000633:toxicity*; D008630:Mercury Poisoning / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control; D008668:Metallothionein / Q000096:biosynthesis*; D051379:Mice; D016566:Organoselenium Compounds / Q000627:therapeutic use; D000623:Porphobilinogen Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D013438:Sulfhydryl Compounds / Q000378:metabolism; D014494:Unithiol / Q000627:therapeutic use; D014508:Urea / Q000097:blood
D000975:Antioxidants; D001555:Benzene Derivatives; D002614:Chelating Agents; D016166:Free Radical Scavengers; D016566:Organoselenium Compounds; D013438:Sulfhydryl Compounds; C061132:diphenyldiselenide; D014494:Unithiol; D008627:Mercuric Chloride; D014508:Urea; D008668:Metallothionein; D000623:Porphobilinogen Synthase; D000111:Acetylcysteine